Hong Kong Drug Patent Portfolio

Hong Kong owns 1 orange book drug protected by 5 US patents Given below is the list of Hong Kong's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US12121582 Injectable pharmaceutical formulations of lefamulin 14 Jun, 2036
Active
US8071643 Pleuromutilin derivatives for the treatment of diseases mediated by microbes 25 Mar, 2033
Active
US9120727 Process for the preparation of pleuromutilins 23 May, 2031
Active
US8153689 Pleuromutilin derivatives for the treatment of diseases mediated by microbes 19 Mar, 2028
Active
US6753445 Pleuromutilin derivatives having antibacterial activity 09 Jul, 2021 Expired


Given below is the list of recent legal activities going on the following drug patents of Hong Kong.

Activity Date Patent Number
Patent litigations
Email Notification 15 Apr, 2025 US12121582
Change in Power of Attorney (May Include Associate POA) 15 Apr, 2025 US9120727
Email Notification 15 Apr, 2025 US8071643
Change in Power of Attorney (May Include Associate POA) 15 Apr, 2025 US8071643
Change in Power of Attorney (May Include Associate POA) 15 Apr, 2025 US12121582
Email Notification 15 Apr, 2025 US9120727
Change in Power of Attorney (May Include Associate POA) 15 Apr, 2025 US8153689
Email Notification 15 Apr, 2025 US8153689
Recordation of Patent eGrant 22 Oct, 2024 US12121582
Mail Patent eGrant Notification 22 Oct, 2024 US12121582
Recordation of Patent Grant Mailed 22 Oct, 2024 US12121582
Patent eGrant Notification 22 Oct, 2024 US12121582
Email Notification 22 Oct, 2024 US12121582
Patent Issue Date Used in PTA Calculation 22 Oct, 2024 US12121582
Email Notification 03 Oct, 2024 US12121582


Hong Kong's Family Patents

Hong Kong drugs have patent protection in a total of 33 countries. It's US patent count contributes only to 16.9% of its total global patent coverage. Click below to unlock the full patent family tree.

Family Patents





Clinical Trials

Recent Clinical Trials by Hong Kong:

Title Lead Sponsor Collaborators Status Phases
Clinical Trials
Stop Air Leak by Talc or Autologous Blood Patch Therapy Chinese University of Hong Kong NA NOT YET RECRUITING
(Sep 1, 2026)
PHASE2, PHASE3
RANKL Inhibition to Combat Sarcopenia in Hip Fracture Patients Prince of Wales Hospital, Shatin, Hong Kong NA NOT YET RECRUITING
(Sep 1, 2026)
PHASE3
Liposomal Bupivacaine Plus Plain Bupivacaine Versus Dexamethasone Plus Plain Bupivacaine in the Supraclavicular Brachial Plexus Block in Patients With Risk Factors for Severe Acute Postoperative Pain The University of Hong Kong NA RECRUITING
(Sep 1, 2026)
PHASE3
Finerenone for Premature Ovarian Insufficiency (POI) The University of Hong Kong-Shenzhen Hospital NA NOT YET RECRUITING
(Sep 1, 2026)
PHASE2
Effects of Kudzu Root (Gegen) on Drug-Metabolizing Enzymes and Blood Clotting in Healthy Volunteers Chinese University of Hong Kong NA COMPLETED
(Sep 1, 2026)
PHASE1
Open-Label Study of HTD1801 in Adult Subjects With Primary Biliary Cholangitis HighTide Therapeutics (Hong Kong) Limited NA COMPLETED
(Aug 1, 2026)
PHASE2
Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer Acerand Therapeutics (Hong Kong) Limited NA RECRUITING
(Aug 1, 2026)
PHASE1
Chinese Medicine for Patients With Psoriasis Chinese University of Hong Kong NA COMPLETED
(Jul 1, 2026)
PHASE2
An Innovative Chinese Herbal Formula for the Treatment of Gout Chinese University of Hong Kong NA COMPLETED
(Jul 1, 2026)
PHASE2
Colchicine Use in Intracranial Atherosclerotic Disease Chinese University of Hong Kong NA RECRUITING
(Jul 1, 2026)
PHASE2
JS207 a Bispecific Antibody Against PD1-VEGF in Nasopharyngeal Carcinoma Chinese University of Hong Kong NA RECRUITING
(Jul 1, 2026)
PHASE2
Gene Therapy for Patients With Transfusion-Dependent β-Thalassemia Prince of Wales Hospital, Shatin, Hong Kong NA NOT YET RECRUITING
(Jul 1, 2026)
PHASE2
Perioperative Haemostasis, Procedure-Related Pain After Physiological or Pharmacological Modifications of Local Anaesthesia Around the Eyes Prince of Wales Hospital, Shatin, Hong Kong NA NOT YET RECRUITING
(Jul 1, 2026)
PHASE3
GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD) Chinese University of Hong Kong NA RECRUITING
(Jun 1, 2026)
PHASE2
Phase 2 Study to Evaluate EI-001 in Non-segmental Vitiligo Patients Elixiron Immunotherapeutics (Hong Kong) Ltd. NA RECRUITING
(Jun 1, 2026)
PHASE2
GLP-1 Receptor Agonist in Primary Intracerebral Hemorrhage: A Phase 2 Randomized Trial Chinese University of Hong Kong NA NOT YET RECRUITING
(May 1, 2026)
PHASE2
The Application of Pressured Intraperitoneal Aerosol Chemotherapy (PIPAC) for Peritoneal Surface Malignancies The University of Hong Kong NA RECRUITING
(Apr 1, 2026)
PHASE2
A Trial on Fezolinetant for Vasomotor Symptoms in Men Receiving Androgen Deprivation Therapy (ADT) Chinese University of Hong Kong NA NOT YET RECRUITING
(Apr 1, 2026)
PHASE2
Liposomal Bupivacaine With Standard Bupivacaine Versus Dexmedetomidine With Standard Bupivacaine The University of Hong Kong NA COMPLETED
(Mar 1, 2026)
PHASE3
Levonorgestrel-piroxicam Versus Ulipristal Acetate for Emergency Contraception The University of Hong Kong NA RECRUITING
(Mar 1, 2026)
PHASE3
Aspirin Continuation or Interruption in Patients at Moderate Risk for Cardiovascular Events Undergoing Colonoscopy and/or Polypectomy Chinese University of Hong Kong NA RECRUITING
(Mar 1, 2026)
PHASE3
Personalized Antiemetic Regimen According to Patients' Pharmacogenetic Profile Chinese University of Hong Kong NA RECRUITING
(Mar 1, 2026)
PHASE2
Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML The University of Hong Kong NA NOT YET RECRUITING
(Mar 1, 2026)
PHASE2


Hong Kong Drug List

Given below is the complete list of Hong Kong's drugs and the patents protecting them.


1. Xenleta

Xenleta is protected by 5 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US12121582 Injectable pharmaceutical formulations of lefamulin 14 Jun, 2036
(9 years from now)
Active
US8071643 Pleuromutilin derivatives for the treatment of diseases mediated by microbes 25 Mar, 2033
(6 years from now)
Active
US9120727 Process for the preparation of pleuromutilins 23 May, 2031
(4 years from now)
Active
US8153689 Pleuromutilin derivatives for the treatment of diseases mediated by microbes 19 Mar, 2028
(1 year, 4 months from now)
Active
US6753445 Pleuromutilin derivatives having antibacterial activity 09 Jul, 2021
(5 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xenleta's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Hong Kong News

Navigating the Complexities of Double Patenting Across Multiple Jurisdictions - Mondaq

04 Mar, 2026

Envoy Medical secures three additional patents to enhance its standing in the cochlear implant industry.

25 Feb, 2026

Sales of Ozempic in China decline for the first time as competitors enter the market - Business Day

05 Feb, 2026

Takeda Partners with China's Innovent to Create Cancer Treatments - Bloomberg.com

22 Oct, 2025

See More